Aardvark Therapeutics (AARD) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by CEO, who also served as Chairman; CFO acted as Secretary and an independent auditor was introduced.

• Agenda included election of two Class I directors, ratification of the independent auditor, and approval of stock option repricing.

• Rules of conduct and procedures were outlined, with validated stockholders allowed to ask questions on agenda items.

Board and executive committee updates

• Two current directors, Jeffrey Chi and Victor Tong Jr., were nominated for re-election as Class I directors to serve until the 2029 Annual Meeting.

• No advance notice of other director nominations was received.

Shareholder proposals

• No additional shareholder proposals were received for this annual meeting.